Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company’s lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver.
Apellis Pharmaceuticals, Inc.
Unlock to Claim this listing
Add / Modify Company
3.8
Overall Excellence Rating
Industry
HealthcareCategory
Biotech & PharmaceuticalsESG/Ethical Impact
Apellis’ focus on drug development could indirectly contribute to environmental sustainability by advancing treatments that improve patients’ health and reduce the overall burden on healthcare systems. Sustainable Practices: The company might focus on efficient use of resources in its operations, such as energy-efficient facilities and sustainable supply chain practices.Apellis’ core business of developing therapies could have a significant positive impact on patient health and well-being, addressing unmet medical needs. Healthcare Access: The company’s focus on rare diseases could contribute to accessible and advanced healthcare solutions for underserved patient populations.Clinical Standards: Adherence to ethical and clinical standards is essential for maintaining patient trust and regulatory compliance in drug development. Transparency: Apellis’ commitment to transparency and ethical conduct likely reflects in its corporate governance practices.Apellis’ financial sustainability comes from the development and potential commercialization of innovative therapies. Investor Relations: The company’s ESG efforts can influence investor perception, especially for those seeking investments aligned with ethical healthcare innovations.The company’s ESG initiatives can resonate with investors interested in both financial returns and ethical medical advancements.Apellis’ therapies directly impact patient lives by addressing serious medical conditions and improving health outcomes.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us

Awards Received
2023
Revenues
$75,000,000.00
Website Traffic
Employee Rating
3.6
Customer Rating
4.6
Company Size
100-1000
ESG Risk Rating
3